PharmaTalkRadio

Latest Episodes:

Merck's Strategy to Mobilize Mobile Efforts and Engineer for Scale Apr 30, 2020

Show notes

This podcast presents a session from Merck on Mobilizing Mobile Efforts and Engineering for Scale at the 2019 Mobile in Clinical Trials conference. Mobile tool/device implementation has been widely accepted, tested, and piloted in clinical research. With the bar set, Merck looks to challenge it and create an ecosystem that continues to set the bar higher with a scalable model. In this session, Kai Bode walks the audience through their approach to coordinating and prioritizing digital efforts, building a prototype to test devices, mobilizing their mobile devices, mobile patient screenings, finding a workaround to perceived barriers and/or premature acceptance of timelines/processes and lessons learned. Speaker: Kai Bode, Director, Digital and Analytics Technologies, Merck The 2020 Mobile in Clinical Trials Conference will take place on September 21. Learn more here.

What Does a Successful Digital Trial Look Like? Apr 30, 2020

Show notes

This podcast presents a panel discussion on What a Successful Digital Trial Looks Like from the 2019 Mobile in Clinical Trials conference. Including: What is a digital trial?Is a common definition needed in order to scale for success?What does success look like? Fully remote, data sharing, device/tool implementation?How do we measure success? And when?What about accessibility?patient/investigator experience?tool/device effectiveness?data quality and usability?did digital help answer the necessary clinical question?did it ensure representative patients in the study? Moderator: Craig Lipset, Former Head of Clinical Innovation, Pfizer Panelists: Jennifer Goldsack, MBA, Executive Director, Digital Medicine Society (DiMe) Jacob LaPorte, PhD, Co-founder & VP, Global Head of Novartis Biome, Novartis The 2020 Mobile in Clinical Trials event will take place on September 21. Learn more here.

Advocating for People Managing Hermansky-Pudlak Syndrome Apr 29, 2020

Show notes

In the third episode of our series highlighting rare diseases, Conference Forum reporter Danny McCarthy sits down with Fernando Albertorio, PhD, to discuss Hermansky-Pudlak Syndrome. Dr Albertorio is co-founder of Sunu, Inc, which creates wearable, IoT and mobile technology that empowers independence for people who a blind and visually impaired. Dr Albertorio is also an advocate for increasing awareness and treatments for managing Hermansky-Pudlak Syndrome (HPS). HPS is an extremely rare autosomal recessive disorder, characterized by albinism, visual impairment, and a platelet dysfunction that results in prolonged bleeding. There are currently 10 known types of HPS. In the episode, Dr Albertorio mentions several websites for more information: HPSNetwork.org, GlobalGenes.org and Sunu.com.

Maintaining Clinical Trial Patient Engagement in COVID with Be the Partner Apr 29, 2020

Show notes

The COVID-19 pandemic has meant that, more and more, clinical trials are being disrupted or interrupted completely. Without the continuous momentum and contact, trials will lose patients as gaps in studies lengthen. To combat that, Be the Partner designed “Bridge,” a new solution on their Patient Portal specifically for continuing secure, ongoing connectivity with trial patients during any temporary pauses in trials as a result of COVID-19. The end goal of “Bridge” is to maintain patient engagement throughout the trial’s indefinite pause and aid in a successful relaunch at the appropriate time. For more information go to or contact www.bethepartner.com.

Setting Up Therapeutic + Vaccine Programs for COVID-19: Lessons Learned Apr 28, 2020

Show notes

PharmaTalk Radio's Valerie Bowling welcomes guest, Kent Thoelke, EVP and CSO at PRA Health Sciences on his experience in rapidly setting up both therapeutic and vaccine focused programs for COVID-19. More specifically, they discuss lessons learned, what the new normal will look like for clinical trials and serving the needs of thousands of people who are currently in clinical trials. Guest Bio: Kent Thoelke is Executive Vice President and Chief Scientific Officer at PRA Health Sciences. Mr. Thoelke provides corporate oversight and strategy for Scientific & Medical Affairs, Pharmacovigilance & Patient Safety, Therapeutic Centers of Excellence, Real World Data, Patient Access & Experience, Digital Health & Virtual Trials, and their integration into operational delivery. Information about PRA Health Sciences, visit PRAH.com Information about upcoming conferences and podcasts on medicine development, visit theconferenceforum.org

Understanding Spinal Muscular Atrophy: A Chief Scientific Officer's Perspective Apr 14, 2020

Show notes

In the second episode of a three-part series dedicated to highlighting rare disease, Conference Forum reporter Danny McCarthy sits down with C Frank Bennett, PhD, of Ionis Pharmaceuticals, to discuss Spinal Muscular Atrophy. Dr Bennett is Executive Vice President and Chief Scientific Officer at Ionis Pharmaceuticals, and one of the founding members of the company. He is responsible for continuing to advance antisense technology and expanding Ionis drug discovery platform. Dr. Bennet is a co-recipient of the 2019 Breakthrough Prize in Life Sciences for his contributions to the discovery and development of SPINRAZA® (nusinersen). Spinal muscular atrophy is a genetic, degenerative neuromuscular disorder characterized by weakness and wasting in muscles used for movement. It is caused by a loss of specialized nerve cells, called motor neurons that control muscle movement. Dr Bennett includes two sources of information about Ionis and SMA: Ionispharma.com and Spinraza.com.

Changing How We Treat Systemic Sclerosis Mar 19, 2020

Show notes

In this three-part series dedicated to the physician's perspective on living with a rare disease, Conference Forum reporter Danny McCarthy sits down with Tracy Frech, MD, to discuss Systemic Sclerosis. Tracy Frech, MD, is a rheumatologist at the University of Utah. At the university, she is the Director of the Systemic Sclerosis (SSc, scleroderma) Clinic at the University of Utah Hospital and the Director of Clinical Trials for the Division of Rheumatology. In her work, Dr Frech treats patients with, and runs clinical trials on, systemic sclerosis, a complex autoimmune disease characterized by pervasive inflammation and fibrosis, and can lead to progressive vascular and organ damage. Dr Frech talks about the disease, current treatment and taking a more holistic approach to treating SSc. In the interview, Dr Frech references the education resource TotalSSc.com., a new disease education campaign website for healthcare providers focused on the “totality in systemic sclerosis”.

New Opportunities for Cell Therapy Combinations Mar 10, 2020

Show notes

In this podcast moderated by Dr Michael Kalos, Janssen Oncology, you will hear a panel discussion from the 2019 IO Combinations 360° conference. Topic points include: What are the new opportunities in cell therapy for combinations?What the challenges are going to be with the microenvironment?What is being done to engineer cell therapy?How do you develop CARs and TCRs that deliver payloads?How do you manufacture all of this beyond mouse models to figure out how to effectively do this in patients?How do you actually go about designing trials and testing hypothesis?How do you create the regulatory framework to do these types of studies?How do you engage with regulatory agencies to get these things moving? Panelists include: Sharon Benzeno, PhD, MBA, Adaptive BiotechnologiesChaohong Fan, MD, PhD, FDABruce Levine, PhD, University of PennsylvaniaMark Stewart, PhD, Friends of Cancer ResearchBahram Valamehr, PhD, Fate Therapeutics To learn more about the upcoming IO Combinations 360° conference please visit, www.iocombinations360.com

PD1 Resistance with a Multi-Omic Approach Mar 10, 2020

Show notes

Anti-PD-1 therapy has transformed cancer care but most patients do not respond. It is increasingly clear that there will be no single biomarker of response to a PD-1, and that a multi-omic approach will be required. In this podcast, first recorded at the 4th annual IO Combinations 360° conference, Dr Danny Wells, Parker Institute for Cancer Immunotherapy will address: Orthogonality and correlation of response biomarkers across histologiesIntegration of multi-omic data sets for mechanistic insights into tumor immunobiologyThe translational approaches to PD1 resistance program at the Parker Institute To learn more about the upcoming IO Combinations 360° conference please visit, www.iocombinations360.com

Updates on PARP Inhibition Mar 09, 2020

Show notes

In this podcast, first recorded at the 4th annual IO Combinations 360° conference, Dr Darren Hodgson, AstraZeneca presented updates on PARP inhibition. Topics include: Strategies to target homologous recombination repair deficiencyMonotherapy indications and current development landscapeScientific hypotheses being explored in olaparib combinations To learn more about the upcoming IO Combinations 360° conference please visit, www.iocombinations360.com

Our TOPPODCAST Picks

Follow Us

Stay Connected

Related Podcasts

Links

Stay Connected

Our TOPPODCAST Picks

Follow Us

Stay Connected

PharmaTalkRadio

Related Podcasts

1

2

3

4

5

6